AU2022245300B2 - Device for treating anaphylaxis - Google Patents

Device for treating anaphylaxis

Info

Publication number
AU2022245300B2
AU2022245300B2 AU2022245300A AU2022245300A AU2022245300B2 AU 2022245300 B2 AU2022245300 B2 AU 2022245300B2 AU 2022245300 A AU2022245300 A AU 2022245300A AU 2022245300 A AU2022245300 A AU 2022245300A AU 2022245300 B2 AU2022245300 B2 AU 2022245300B2
Authority
AU
Australia
Prior art keywords
epinephrine
api
dose
metered dose
dose inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022245300A
Other languages
English (en)
Other versions
AU2022245300A1 (en
Inventor
Warren Hugh Finlay
George Harry LUCIUK
Andrew Robert MARTIN
Conor Aidan RUZYCKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kokua Pharma Inc
Original Assignee
Kokua Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kokua Pharma Inc filed Critical Kokua Pharma Inc
Publication of AU2022245300A1 publication Critical patent/AU2022245300A1/en
Assigned to Kokua Pharma Inc. reassignment Kokua Pharma Inc. Amend patent request/document other than specification (104) Assignors: 1232176 B.C. LTD
Application granted granted Critical
Publication of AU2022245300B2 publication Critical patent/AU2022245300B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/02—Equipment for testing the apparatus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Meat And Fish (AREA)
  • Surgical Instruments (AREA)
  • Non-Portable Lighting Devices Or Systems Thereof (AREA)
AU2022245300A 2021-03-23 2022-03-23 Device for treating anaphylaxis Active AU2022245300B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165102P 2021-03-23 2021-03-23
US63/165,102 2021-03-23
PCT/US2022/021612 WO2022204328A1 (en) 2021-03-23 2022-03-23 Device for treating anaphylaxis

Publications (2)

Publication Number Publication Date
AU2022245300A1 AU2022245300A1 (en) 2023-09-14
AU2022245300B2 true AU2022245300B2 (en) 2026-04-02

Family

ID=81307871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022245300A Active AU2022245300B2 (en) 2021-03-23 2022-03-23 Device for treating anaphylaxis

Country Status (20)

Country Link
US (1) US20220331237A1 (cg-RX-API-DMAC7.html)
EP (2) EP4188332B1 (cg-RX-API-DMAC7.html)
JP (2) JP2024515446A (cg-RX-API-DMAC7.html)
KR (1) KR20230165764A (cg-RX-API-DMAC7.html)
CN (1) CN117083054A (cg-RX-API-DMAC7.html)
AU (1) AU2022245300B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023019156A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212189A1 (cg-RX-API-DMAC7.html)
DK (1) DK4188332T3 (cg-RX-API-DMAC7.html)
ES (2) ES3025005T3 (cg-RX-API-DMAC7.html)
FI (1) FI4188332T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250566T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071185T2 (cg-RX-API-DMAC7.html)
IL (1) IL305534A (cg-RX-API-DMAC7.html)
LT (1) LT4188332T (cg-RX-API-DMAC7.html)
PL (1) PL4188332T3 (cg-RX-API-DMAC7.html)
PT (1) PT4188332T (cg-RX-API-DMAC7.html)
RS (1) RS66787B1 (cg-RX-API-DMAC7.html)
SI (1) SI4188332T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022204328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514995B2 (en) * 2021-02-15 2026-01-06 Glenmark Pharmaceuticals Limited Metered dose inhalers of fluticasone or an ester thereof
WO2025072756A1 (en) * 2023-09-28 2025-04-03 Kokua Pharma Inc. Device, methods, and uses for treating acute allergic reactions
WO2025170986A1 (en) * 2024-02-06 2025-08-14 Kindeva Drug Delivery L.P. Drug delivery device
US20260007598A1 (en) * 2024-07-05 2026-01-08 Honeywell International Inc. Compositions, devices and methods for respritory delivery of active pharmaceutical ingredients
US12496272B1 (en) * 2024-07-31 2025-12-16 Amphastar Pharmaceuticals, Inc. Stable epinephrine suspension formulation for inhalation with HFO propellant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095681A2 (en) * 2008-02-01 2009-08-06 Vectura Limited Suspension formulations
US8367734B1 (en) * 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324250D0 (en) * 1993-11-25 1994-01-12 Minnesota Mining & Mfg Inhaler
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1531794B1 (en) * 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Inhalable epinephrine
AU2004249166B2 (en) * 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
WO2006101882A2 (en) * 2005-03-16 2006-09-28 Honeywell International Inc. Medicament delivery formulations, devices and methods
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
SI2627386T1 (sl) * 2010-10-12 2015-10-30 Ivax Pharmaceuticals Ireland Nosna pršilna naprava
US20120204871A1 (en) * 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
WO2014033057A1 (en) * 2012-08-29 2014-03-06 Chiesi Farmaceutici S.P.A. Aerosol inhalation device
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US9717683B1 (en) * 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
ES2791775B2 (es) * 2018-02-06 2023-01-20 Aegis Therapeutics Llc Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367734B1 (en) * 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
WO2009095681A2 (en) * 2008-02-01 2009-08-06 Vectura Limited Suspension formulations

Also Published As

Publication number Publication date
KR20230165764A (ko) 2023-12-05
JP2024515446A (ja) 2024-04-10
EP4188332A1 (en) 2023-06-07
CN117083054A (zh) 2023-11-17
EP4188332B1 (en) 2025-02-12
ES3025005T3 (en) 2025-06-05
RS66787B1 (sr) 2025-06-30
EP4545122C0 (en) 2026-07-15
AU2022245300A1 (en) 2023-09-14
IL305534A (en) 2023-10-01
CA3212189A1 (en) 2022-09-29
PL4188332T3 (pl) 2025-11-24
LT4188332T (lt) 2025-05-12
EP4545122A2 (en) 2025-04-30
WO2022204328A1 (en) 2022-09-29
SI4188332T1 (sl) 2025-07-31
FI4188332T3 (fi) 2025-05-06
HUE071185T2 (hu) 2025-08-28
JP2026094267A (ja) 2026-06-09
HRP20250566T1 (hr) 2025-06-20
ES3076082T3 (en) 2026-08-11
EP4545122A3 (en) 2025-05-07
DK4188332T3 (da) 2025-05-05
US20220331237A1 (en) 2022-10-20
PT4188332T (pt) 2025-04-17
BR112023019156A2 (pt) 2023-10-17
EP4545122B1 (en) 2026-07-15

Similar Documents

Publication Publication Date Title
EP4188332B1 (en) Device for treating anaphylaxis
EP3384931B1 (en) Formoterol superfine formulation
US20060018840A1 (en) Aerosolizable formulation comprising nicotine
AU2018200965A1 (en) Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN103052378A (zh) 包含磷酸二酯酶抑制剂的药物制剂
CA2847817A1 (en) Treating cough and tussive attacks
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
Dongare et al. An overview of recently published patents on pulmonary drug delivery devices
HK40087057A (en) Device for treating anaphylaxis
HK40087057B (en) Device for treating anaphylaxis
WO2025072756A1 (en) Device, methods, and uses for treating acute allergic reactions
HK40102631A (en) Device for treating anaphylaxis
EP3212212B1 (en) Powder formulation
US20090180969A1 (en) Pharmaceutical formulation comprising an anticholinergic drug
Hindle Aerosol drug delivery
HK1079425B (zh) 福莫特罗超细制剂

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 MAY 2026